WHAT IS CLAIMED IS:

1. A nitrosated and/or nitrosylated phosphodiesterase inhibitor having the formula NO_n-PDE wherein is 1 or 2.

2. The nitrosated and/or nitrosylated phosphodiesterase inhibitor of claim 1 which is nitrosylated or nitrosated through an oxygen, sulfur, carbon or nitrogen site on the phosphodiesterase inhibitor.

3. The nitrosated and/or nitrosylated phosphodiesterase inhibitor of claim 1 which is selected from the group consisting of:

(I) compounds having the structure:



I

wherein,

R_1 is alkoxy, cycloalkoxy, halogen, or



;

R_2 is hydrogen, alkoxy, or haloalkoxy; and

R_3 is selected from:

(i)



(ii)



(iii)



(iv)



(v)



(vi)



(vii)



(viii)



(ix)



(x)



wherein

D is selected from (i) -NO; (ii) $-NO_2$; (iii) $-C(R_d)-O-C(O)-Y-Z-[C(R_e)(R_f)]_p-T-Q$ in which R_d is hydrogen, lower alkyl, cycloalkyl, aryl, alkylaryl, aryl or heteroaryl, Y is oxygen, sulfur, or NR_i in which R_i is hydrogen, lower alkyl, R_e and R_f at each occurrence are independently selected from hydrogen, lower alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, amino, alkylamino, amido, alkylamido, dialkylamino, carboxy, or taken together are carbonyl, cycloalkyl or bridged cycloalkyl, p is an integer from 1 to 6, T is a covalent bond, oxygen, sulfur or nitrogen, Z is selected from a covalent bond, alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl or arylheterocyclic ring, and Q is selected from -NO or $-NO_2$; (iv) $-C(O)-T^1-Z-[C(R_e)(R_f)]_p-T^2-Q$ wherein T^1 and T^2 are independently selected from T and R_e, R_f, p, Q, Z, and T are as defined in this specification; (v) $-C(O)-Z-[G-[C(R_e)(R_f)]_p-T-Q]_p$ wherein G is (*i*) a covalent bond; (*ii*) -T-C(O)-; (*iii*) -C(O)-T, or (*iv*) Y, and wherein R_e, R_f, p, Q, T, Y, and Z are as defined in this specification; (v) $-C(O)-T[C(R_y)(R_z)]_p$ wherein R_y and R_z are independently selected from $-T^1-[C(R_e)(R_f)]_p-G-[C(R_e)(R_f)]_p-T^2-Q$ wherein G, R_e, R_f, p, Q, T, T^1, and T^2 are as defined in this specification;

R_4 is selected from (i) hydrogen, (ii) $-C(R_d)-O-C(O)-Y-Z-[C(R_e)(R_f)]_p-T-Q$, (iii) $-C(O)-T^1-[C(R_e)(R_f)]_p-T^2-Q$, (iv) $-C(O)-Z-[G-[C(R_e)(R_f)]_p-T-Q]_p$; and wherein R_d, R_e, R_f, p, G, T, T^1, T^2, Q, Y, and Z are defined as in this specification;

R_5 is selected from a lone pair of electrons or $-C(R_d)-O-C(O)-Y-Z-[C(R_e)(R_f)]_p-T-Q$ wherein R_d, R_e, R_f, p, T, T^1, T^2, Q, Y, and Z are defined as in this specification;

R_{11} and R_{12} are independently selected from hydrogen or R_4 wherein R_4 is as defined in this specification with the provision that R_{11} and R_{12} are not both hydrogen;

X is a halogen and;

D_1 is selected from D or hydrogen and wherein D is as defined in this specification.

(II) compounds having the structure:



II

wherein,

R_4 is as defined in this specification;

R_8 is selected from hydrogen or lower alkyl;

R_9 is selected from hydrogen or halogen; and

R_{10} is selected from:

(i) hydrogen

(ii)



(iii)



wherein R_8 is as defined in this specification.

(III) compounds having the structure:



III

wherein,

E is selected from nitrogen or -CH-;

G is selected from nitrogen or -C(R_8)-;

R_{21} is selected from:

(i)



(ii)



R_{22} is selected from R_{12} or lower alkyl; and

R_8, R_{11}, and R_{12} are as defined in this specification

(IV) compounds having the structure:



IV

wherein,

F is selected from $-CH_2-$ or sulfur;

R_4 and R_8 are as defined in this specification; and

R_{13} is selected from:

(i)



(ii)



(iii)



(iv)



(v)



(vi)



(vii)



wherein,

R_6 and R_7 are independently selected from hydrogen or R_4 wherein R_4 is as defined in this specification.

(V) compounds having the structure:



V

wherein,

R_4 is as defined in this specification; and

R_{14} is selected from:

(i)



(ii)



(iii)



(iv)



wherein R_6 is as defined in this specification.

(VI) compounds having the structure:



VI

wherein,

R_{15} is hydrogen, lower alkyl, R_4, or $-(CH_2)_4-C(CH_3)_2-O-D_1$;

R_{16} is lower alkyl; and

R_{17} is hydrogen, lower alkyl, $CH_3-C(O)-CH_2-$, CH_3-O-CH_2-, or D with the provision that either R_{15} or R_{17} must be selected to contain D and wherein D and D_1 are as defined in this specification.

(VII) compounds having the structure:



VII

wherein,

R_4 and R_8 are as defined in this specification and

R_{18} is selected from:

(i) 

(ii) 

and wherein R_8 is as defined in this specification.

(VIII) compounds having the structure:



VIII

wherein,

R_{19} is selected from:

(i) 

(ii) 

(iii) 

(iv) 

and wherein R_4, R_{11}, and R_{12} are defined as in this specification.

(IX) compounds having the structure:



IX

wherein,

R_{20} is selected from:

(i) 

(ii) 

and wherein R_4 is defined as in this specification.

(X) compounds having the structure:



X

wherein,

a is an integer from 2 to 3 and D and D_1 are defined as in this specification.

(XI) compounds having the structure:



XI

wherein D and D_1 are defined as in this specification.

(XII) compounds having the structure:



XII

wherein,

J is selected from:

(i) 

(ii) 

K is selected from:

(i) 

(ii) 

wherein V is carbon or nitrogen;

R_{23}, R_{24}, R_{25}, R_{26}, R_{27}, R_{28}, R_{29}, and R_{30} are independently selected from hydrogen, halogen, alkoxy, nitrile, carboxamido, or carboxyl; and

wherein p, R_e, R_f, T, T^1, T^2, Y and D are defined as in this specification.

(XIII) compounds having the structure:



XIII

wherein,

R_{31} is alkyl, halogen, haloalkyl, or haloalkoxy;

R_{32} is selected from D_1 or -C(O)-R_8; and

wherein D_1 and R_8 are defined as in this specification.

4. A composition comprising a therapeutically effective amount of the phosphodiesterase inhibitor of claim 1 and a one to ten fold molar excess of a compound that donates, transfers or releases nitrogen monoxide as a charged species, i.e., nitrosonium (NO^+), or nitroxyl (NO^-), or as the neutral species, nitric oxide (NO•)or induces the production of endogenous EDRF and a pharmaceutically acceptable carrier.

5. A method for treating male impotence in humans which comprises administering to an individual in need thereof a therapeutically effective amount of a nitrosated or nitrosylated PDE inhibitor of claim 1.

6. A method for treating female sexual dysfunction in humans which comprises administering to an individual in need thereof a therapeutically effective amount of a nitrosated or nitrosylated PDE inhibitor of claim 1.

7. A method for treating anal disease in humans which comprises administering to an individual in need thereof a therapeutically effective amount of a nitrosated or nitrosylated PDE inhibitor of claim 1.

Appendix 1 – Pending Claims

a1

8. (New) A method of treatment, in an organism, of a vascular condition, comprising administration of at least one agent at a level which enhances NO and which does not appreciably alter normal systemic vascular tone in said organism.

9. (New) A method for treating sexual dysfunction in a female individual, comprising administering to the vagina, vulvar area and/or urethra of the individual a pharmaceutical formulation that comprises an effective amount of a nitrovasodilator selected from the group consisting of sodium nitroprusside, diazenium diolates, molsidomine, linsidomine chlorohydrate, S-nitrosothiols, organic nitrates, pharmacologically acceptable salts, esters, analogs, derivatives, prodrugs and inclusion complexes of any of the foregoing, and combinations thereof.

10. (New) A method of enhancing sexuality in a female having a clitoris comprising the step of topically administering to a surface of the clitoris a composition whose primary agent is a vasodilator and whose secondary agent is a carrier in which the vasodilator is dispersed to deliver it directly to said surface so that it is retained and absorbed thereby, said composition being in a formulation and in a dosage which is substantially free of toxicity and therefore does not give rise to an adverse reaction.